Background illustration for clinical trials search

Paid Clinical Trials Richmond

Discover 561 paid clinical trials in Richmond, Virginia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

for
Locally Advanced Pancreatic Adenocarcinoma,
Location: Richmond VA, Washington D.C. DC, Pittsburgh PA,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04172532

Phase1, Phase2, Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

for
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma,
Location: Richmond VA, New York NY, Charleston SC, Rochester NY,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05890352

Phase2, Recruiting

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

for
Breast Cancer, Breast Cancer Recurrent
Location: Richmond VA, New York NY, London, Toronto, Oshawa,
Sponsor: University Health Network, Toronto

Sex: Female

Age: 18 - 70+

Code: NCT05592938

Recruiting

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

for
Breast Cancer
Location: Richmond VA, Midlothian VA, Lynchburg VA, Bethesda MD,
Sponsor: Exact Sciences Corporation

Sex: All

Age: 18+

Code: NCT06401421

Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

for
Multiple Myeloma
Location: Richmond VA, Durham NC, New York NY, Cleveland OH,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06500884

Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

for
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Location: Richmond VA, Columbus OH, Derby CT, New Haven CT,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06465316

Phase1, Recruiting

Vitamin D for Prostate Endocrine Therapy

for
Stage I Prostate Cancer AJCC v8,
Location: Richmond VA, Mechanicsville VA, Midlothian VA,
Sponsor: University of Rochester

Sex: Male

Age: 50+

Code: NCT05838716

Phase3, Recruiting

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

for
Recurrent Diffuse Large B-Cell Lymphoma,
Location: Richmond VA, Columbus OH, Minneapolis MN
Sponsor: Yazeed Sawalha

Sex: All

Age: 18+

Code: NCT06536049

Phase1, Phase2, Recruiting

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for
Myelodysplastic Syndrome
Location: Richmond VA, Bethesda MD, Greenville NC, Durham NC,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06577441

Phase2, Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

for
Nodular Lymphocyte Predominant B-Cell Lymphoma,
Location: Richmond VA, Charlottesville VA, Winston-Salem NC,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05886036

Phase2, Recruiting

Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer

for
Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8,
Location: Richmond VA, Charlottesville VA, Durham NC, Raleigh NC,
Sponsor: NRG Oncology

Sex: Female

Age: 18+

Code: NCT06388018

Phase2, Recruiting

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk

for
Prostate Cancer, Supportive Care
Location: Richmond VA
Sponsor: Virginia Commonwealth University

Sex: Male

Age: 40 - 70+

Code: NCT06237179

Phase1, Phase2, Recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

for
Advanced Malignant Solid Neoplasm,
Location: Richmond VA, Charlottesville VA, New York NY,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06311214

Phase2, Recruiting

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

for
Melanoma, Squamous Cell Carcinoma of Head and Neck
Location: Richmond VA, New Haven CT, Boston MA
Sponsor: IO Biotech

Sex: All

Age: 18+

Code: NCT05280314

Phase2, Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

for
Advanced Melanoma
Location: Richmond VA, Charlottesville VA, Washington D.C. DC,
Sponsor: Immunocore Ltd

Sex: All

Age: 18+

Code: NCT06112314

Phase3, Recruiting

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

for
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma,
Location: Richmond VA, Norfolk VA, Washington D.C. DC,
Sponsor: Lyell Immunopharma, Inc.

Sex: All

Age: 18+

Code: NCT05826535

Phase1, Phase2, Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

for
B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma,
Location: Richmond VA, Bethesda MD, New York NY, Buffalo NY,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT05006716

Phase1, Phase2, Recruiting

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for
Melanoma
Location: Richmond VA, Charlottesville VA, Fairfax VA,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06246916

Phase3, Recruiting

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

for
Non-small Cell Lung Cancer
Location: Richmond VA, Fairfax VA, Arlington VA,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT06712316

Phase2, Phase3, Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

for
Mantle Cell Lymphoma, B Cell Lymphoma
Location: Richmond VA, Charlottesville VA, Gainesville VA,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06742996

Phase3, Recruiting